Enhanced Effects Found in Psychedelic Mushrooms Psilocybin

Recent research highlights that the effects of psychedelic mushrooms, when consumed in their full extract form, are significantly more profound than those of isolated, synthetically produced psilocybin. This discovery sheds new light on the potential for psychedelic-assisted therapy and introduces the concept of an "entourage effect," akin to the phenomenon observed in cannabis, where the interaction of multiple components enhances the overall experience.

soko magic mushrooms
soko magic mushrooms

Magic Mushrooms and the research

Researchers from a collaborative team across prestigious institutions, including Hadassah Medical Center at Hebrew University, Human Metabolome Technologies in Boston, and Parow Entheobiosciences in Chicago, have noted that clinical trials have traditionally focused on synthetic psilocybin. However, their recent findings suggest that the complex mix of compounds in psychedelic mushrooms might offer additional therapeutic benefits.

According to their study, published in the journal Molecular Psychology, the full-spectrum psychedelic mushroom extract (PME) not only has a stronger impact on synaptic plasticity—a key aspect of brain function and therapy—but also induces effects that last longer than those of synthetic psilocybin (PSIL) alone.

This research opens up exciting avenues for exploring the therapeutic use of natural psychedelic compounds, offering new hope for individuals who have not benefited from standard psychiatric treatments. The study emphasizes the potential advantages of utilizing full-spectrum extracts over single compounds, highlighting the importance of diverse compounds in enhancing therapeutic outcomes.

To arrive at these conclusions, the researchers administered either synthesized psilocybin or a comprehensive mushroom extract containing psilocybin 

Psilocin, and several other compounds to adult male mice. They observed the mice's behavior and analyzed brain tissue samples, finding significant differences in the effects of PME on synaptic proteins, which are indicators of neuroplasticity.

Interestingly, while the acute effects on behavior were similar between the two treatments, PME showed a notably stronger influence on synaptic protein levels across several brain regions, suggesting a more potent or distinct therapeutic mechanism compared to PSIL alone.

The study acknowledges the complexity of the mushroom extract and the potential influence of other, not yet measured components. It highlights the ongoing interest in understanding the full spectrum of compounds present in psychedelic mushrooms and their combined effects.

With Psilocybe cubensis as the focus of this study, the researchers caution against generalizing their findings to all psychedelic mushrooms, as the concentration and composition of active compounds can vary significantly.

soko magic mushrooms
soko magic mushrooms

Magic Mushroom psilocybin

This groundbreaking research not only calls for further exploration into the combined effects of mushroom compounds but also challenges the traditional emphasis on purity and consistency in pharmaceutical development. The potential therapeutic benefits of these complex natural extracts may lead to more effective treatments for a variety of conditions, signaling a shift towards a more holistic approach in medicine.

Parallel research in the cannabis field reinforces the idea of an entourage effect, with studies showing enhanced experiences and medical benefits from the combined action of cannabinoids, terpenes, and other plant compounds. This growing body of evidence supports the need for a deeper understanding of how multiple components within natural products interact, potentially unlocking new possibilities for their therapeutic use. 

Magic Mushroom Exploration 

In a groundbreaking move, President Joe Biden has put forth a proposal to reclassify marijuana as a Schedule 3 substance under the Controlled Substances Act, signaling a potential end to over five decades of policies many deem unsuccessful. This change could open doors for scientific research and entrepreneurial ventures. However, this proposal does not address the classification of psilocybin, the active compound in "magic mushrooms," which remains categorized alongside drugs considered more hazardous than fentanyl, despite its growing popularity for therapeutic use and negligible risk of fatal overdose.

magic mushroom
soko magic mushrooms 

Under the current legislation, psilocybin is listed as a Schedule 1 drug

A category that also includes marijuana. This classification complicates research into its safety and therapeutic benefits, requiring a relaxation of regulations for comprehensive study. With marijuana's reclassification potentially on the horizon, speculation arises about whether President Biden or Congress might next consider reclassifying psilocybin.

Andrew Livingston, Director of Economics and Research at Vicente law firm in Denver, believes that while possible, the approach to reclassifying psilocybin would differ from marijuana due to the unique pathways through which psychedelic therapies are being legalized at the state level. These differences have implications for both policymakers and advocates as they navigate the complexities of state and local reforms.

Psychedelic substances, including psilocybin, have been recognized for their medical benefits 

leading to their designation as "breakthrough therapies" for conditions like major depressive disorder by the U.S. Food and Drug Administration in recent years. Despite this, most research funding comes from private donations rather than federal grants. Legal changes at the state level have started to reflect this recognition, with Oregon and Colorado pioneering the legal provision of psilocybin in regulated therapeutic settings.

soko magic mushrroms
soko magic mushrooms 

The push for legalization and the pace at which it is occurring suggest a cautious optimism for the future of psychedelic substances in the United States

Factors influencing this future include outcomes of clinical trials, decisions by federal agencies like the DEA and FDA, and state-level legislative reforms, which have historically driven cannabis legalization. However, the DEA is unlikely to decriminalize drugs without input from higher governmental authorities.

The FDA's consideration of reclassifying marijuana was significantly informed by data from state-regulated programs and research. This underscores the need for states to design their psychedelic legalization efforts in a way that generates useful data for potential federal reform. However, current approaches to psychedelic policy, focusing on therapeutic use rather than consumer products, may not provide the same breadth of data as cannabis regulation.

soko magic mushrooms
soko magic mushrooms

Livingston highlights the importance of considering how state-level regulations can produce meaningful data to support the rescheduling of psychedelics. He points out the disparity in demand and regulatory approaches between cannabis and psychedelics, emphasizing the need for policies that enable the economic viability of psychedelic therapy programs and facilitate involvement from healthcare professionals and patients alike.

Upon ingestion, psilocybin is absorbed into the bloodstream, primarily through the digestive system, and transported to the liver. Here, it undergoes a transformation where enzymes known as alkaline phosphatases convert psilocybin into psilocin, the active compound responsible for the psychedelic effects, through a process called dephosphorylation. This conversion is crucial for the substance's activity in the brain, with a phenomenon known as the 'first pass effect' influencing the efficiency of this conversion.